Compare · GILD vs PTHS
GILD vs PTHS
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Pelthos Therapeutics Inc. (PTHS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PTHS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 1777.2x PTHS ($93.8M).
- Over the past year, GILD is up 24.1% and PTHS is up 43.3% - PTHS leads by 19.3 points.
- GILD has been more active in the news (7 items in the past 4 weeks vs 5 for PTHS).
- GILD has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Gilead Sciences Inc.
- Pelthos Therapeutics Inc.
- Price
- $134.23-1.50%
- $27.95+8.54%
- Market cap
- $166.72B
- $93.8M
- 1M return
- +5.49%
- -1.31%
- 1Y return
- +24.06%
- +43.33%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 1992
- 2024
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 6
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest PTHS
- Director Friedberg Ezra M sold $14,556 worth of shares (558 units at $26.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 81,042 units (SEC Form 4) to cover withholding tax
- Director Pauls Matthew sold $20,561 worth of shares (786 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 14,364 units (SEC Form 4) to satisfy withholding tax
- Director Greenleaf Peter sold $20,827 worth of shares (797 units at $26.13) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 23,884 units (SEC Form 4) to satisfy withholding tax
- Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Director Friedberg Ezra M sold $7,724 worth of shares (283 units at $27.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 81,600 units (SEC Form 4) to satisfy tax liability
- Director Davis Todd C bought $999,983 worth of shares (35,948 units at $27.82), increasing direct ownership by 90% to 75,834 units (SEC Form 4)
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
- CFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)